JW (Cayman) Therapeutics Co. Ltd (JWCTF)

OTCMKTS · Delayed Price · Currency is USD

0.2022

-0.0093 (-4.40%)

At close: Jul 10, 2026

Market Cap	129.66M -27.5%
Revenue (ttm)	42.49M +62.4%
Net Income	-49.83M
EPS	-0.12
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	100
Open	0.2022
Previous Close	0.2115
Day's Range	0.2022 - 0.2022
52-Week Range	0.2022 - 0.6602
Beta	1.81
Analysts	n/a
Price Target	n/a
Est. Earnings	Nov 27, 2026

About JWCTF

JW (Cayman) Therapeutics Co. Ltd, a clinical stage cell therapy company, engages in the research and development, manufacture, and marketing of cellular immunotherapy products in the People’s Republic of China. The company offers cell-based immunotherapies, including CAR-T treatment, a treatment method that uses human immune cells to fight cancer. It offers Carteyva, JWCAR201, and JWCAR239 for the treatment of hematological malignancies, advanced relmacabtagene autoleucel injection (“relma-cel”) as a potential treatment for systemic lupus eryth... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 303

Stock Exchange OTCMKTS

Ticker Symbol JWCTF

Financial Performance

In 2025, JWCTF's revenue was 283.65 million, an increase of 79.28% compared to the previous year's 158.22 million. Losses were -555.29 million, -5.98% less than in 2024.

Financial numbers in CNY Financial Statements